Hair loss on a GLP-1: how common it is per drug, and why
Reviewed 16 sourcesPublished by PepVault
Hair loss on Wegovy, Zepbound and Foundayo per their labels, against placebo and by sex, why fast weight loss triggers shedding, and how long it lasts.

- Last reviewed
- Sources
- 16
- Questions
- 6
- Compounds
- 4
The short answer
In the trials on the labels, 3 to 6% of people on Wegovy, 4 to 5% on Zepbound and 4 to 5% on Foundayo reported hair loss, against 0 to 2% on placebo, and mostly women. It is usually telogen effluvium, a temporary shed that starts around three months after fast weight loss and typically settles within six months. Protein and enough food help.
Evidence: Placebo-controlled trials as summarised in the current FDA labels (Wegovy, Zepbound, Foundayo; Ozempic, Mounjaro and Saxenda list hair loss only from post-approval reports), a 2026 meta-analysis of trials, a 2026 health-records cohort in type 2 diabetes, a retrospective clinic study and reviews of telogen effluvium; the drugs' own share, apart from the weight loss, is not yet settled.

How common is hair loss on Wegovy, Zepbound and other GLP-1s?
Uncommon, but real: on the weight-loss labels it runs a few points above placebo. Each weight-loss label counts it in the placebo-controlled trials the drug was approved on, so the rate on the drug and the rate on placebo sit side by side. The table puts the current labels together, as DailyMed prints them in November 2026.
| Label and dose | Trials the rate comes from | Hair loss on the drug | On placebo |
|---|---|---|---|
| Wegovy injection, 2.4 mg weekly | Three 68-week trials, 2,116 adults with obesity or overweight on the drug, 19% with type 2 diabetes | 3% | 1%1 |
| Wegovy injection, 7.2 mg weekly | Two 72-week trials in adults with obesity, one in type 2 diabetes; 1,311 on 7.2 mg | 6% (3% on the 2.4 mg arm) | 1%1 |
| Wegovy injection, 2.4 mg, ages 12 and up | One 68-week trial, 201 teenagers with obesity, 133 on the drug | 4% | 0%1 |
| Wegovy tablets, 25 mg daily | One 64-week trial, 204 adults | No separate rate; common reactions similar to the injection's | Not given1 |
| Zepbound, 5 / 10 / 15 mg weekly | Two 72-week trials, 2,519 adults with obesity or overweight on the drug, one in type 2 diabetes (the 5 mg rate is from the first trial only) | 5% / 4% / 5% | 1%2 |
| Foundayo, 5.5 / 9 / 17.2 mg daily | Two 72-week trials, 3,155 adults with obesity or overweight on the drug, one in type 2 diabetes | 4% / 4% / 5% | 2%3 |
| Ozempic (injection and tablets), Mounjaro, Saxenda | Their trial tables list no hair loss | Alopecia (hair loss) appears only in post-approval reports, with no rate | Not given4567 |

The labels warn that rates from one drug's trials cannot be compared directly with another's, because the trials ran under different conditions1. Read across a row, drug against its own placebo, before reading down the table.

Why do women report hair loss on a GLP-1 more than men?
Nearly all the cases on the labels are in women. Every label splits it by sex, and the gap is wide.
| Label and pool | Women on the drug | Men on the drug | Women on placebo | Men on placebo |
|---|---|---|---|---|
| Wegovy 2.4 mg, three weight trials | 4% | 0.9% | 2% | 01 |
| Wegovy 7.2 mg, two weight trials | 8.4% | 0.2% | 1.5% | 01 |
| Zepbound, two weight trials | 7.1% | 0.5% | 1.3% | 0%2 |
| Foundayo, two weight trials | 7% | 0.9% | 3% | 0.7%3 |

No label explains the gap. One clue comes from a Korean clinic's records of 140 people with shedding after weight loss: the women had lost weight more slowly than the men before the shed began, 3.1 kg a month on average against 5.0 kg9.
Few people stopped treatment over it. No one on Zepbound stopped because of hair loss, while one person on placebo did2. On Wegovy 7.2 mg, one case of hair loss led to stopping, one to a pause and five to a lower dose1.
Why does a GLP-1 make your hair fall out?
Mostly through the weight loss itself. Wegovy's, Zepbound's and Foundayo's labels all use the same words: the hair loss was associated with weight reduction123. The usual form is telogen effluvium. Each hair follicle cycles between a long growing phase (anagen) and a resting phase (telogen), after which the resting hair falls out. A shock to the body, such as surgery, a high fever, childbirth or a sudden drop in weight, pushes many follicles into rest at the same time, and those hairs shed together about two to four months later89. The hair thins all over rather than in patches.

Eating much less is the second half of the story. People on GLP-1s for weight loss eat 16 to 39% fewer calories, and the 2025 nutrition advisory from four US obesity and nutrition societies notes that below about 1,200 kcal a day for women and 1,800 for men, intakes of iron, zinc, calcium and several vitamins can fall short14. It lists excessive hair loss among the signs of a real nutrient deficiency14. Bariatric surgery shows both patterns: shedding within the first three months is usually telogen effluvium, while shedding that starts around six months after surgery or later is more often tied to nutrient deficiencies15.
Is it the drug or the weight loss?
Not settled. The labels say only that the hair loss was associated with weight reduction123, and a 2026 systematic review says the drugs' direct role is difficult to disentangle from the weight loss and the nutrient gaps that come with it; it asks future studies to track how much and how fast weight came off11. A 2026 dermatology commentary adds that causality has not been established and that a direct effect of GLP-1 drugs on hair follicles has not been shown10. The one hint of such an effect is a 2006 study that found GLP-1 receptors in the hair follicles of mouse skin; whether human follicles carry them is unknown10.
The link itself holds up. A 2026 meta-analysis of nine studies, seven of them randomised trials, with 4,114 people on a GLP-1, put the risk of hair loss at about three times placebo's, with 3.9% of users affected13. It shows outside the trials too: in the health records of adults with type 2 diabetes at one US health system, about 12,000 people starting a GLP-1 had a 37% higher risk of a hair-loss diagnosis than people starting an SGLT-2 inhibitor and 68% higher than those starting a DPP-4 inhibitor, two other diabetes drug classes; the authors call the absolute risk low12.
Two findings fit the weight-loss reading. In a large US records study, people on semaglutide or tirzepatide who were diagnosed with hair loss had a lower BMI at follow-up than those who were not, which the authors read as a sign that the stress of weight loss contributes16. And in a 2025 records study the review cites, tirzepatide, the drug with the largest and fastest weight loss among them, had a higher rate of telogen effluvium than other weight-loss medicines but one close to bariatric surgery's11.
When does GLP-1 hair loss start, and how long does it last?
It starts late and ends on its own. Because the shed lags its trigger, it usually shows around three months after starting the drug10, often while the weight is still coming off. The acute form lasts less than six months; shedding that runs past six months is called chronic telogen effluvium and points to a trigger that keeps going, such as ongoing low intake11. The 2026 commentary expects the hair loss of telogen effluvium to stop once the weight loss stops10.
Commonly reported: noticing more hair in the brush, the shower drain or on the pillow somewhere around months three to five, a thinner ponytail or a wider parting, and the shedding easing once the weight levels off.
What helps with hair shedding on a GLP-1?
Eating enough, especially protein, is what the guidance points to1014. These are published recommendations, not a prescription.
- Eat the protein part of each meal first, while your appetite lasts. The 2025 advisory lists 1.2 to 1.6 g of protein per kg of body weight a day as proposed during active weight loss14.
- Keep an eye on how little you eat: the advisory flags days under about 1,200 kcal for women or 1,800 for men as the range where vitamins and minerals fall short14.
- If your intake has been low for weeks, ask your prescriber whether to check iron, vitamin D and zinc; an uncontrolled study found low levels of all three in many people with telogen effluvium8.
- Skip biotin and vitamin E: the research does not support taking them for this kind of shedding8.
- Talk to your prescriber before changing your dose because of shedding. In the trials that report it, almost no one stopped over it12, and since the shed lags its trigger by about three months, this month's hair fall began well before8.
- Note the date the shedding started and check it again after a few months, so you can tell whether it is easing.
In PepVault, the side-effect log keeps the symptom, how strong it is, the date and your own note, so the start of a shed is on record when you see your prescriber. Log it in PepVault
On Body, your weight chart and the week's change show how fast the weight is coming off, which is the pace this kind of shedding follows. Track your weight in PepVault
When to get help If the hair comes out in patches, the scalp is red, sore or scarred, or the shedding keeps going past about six months, see a dermatologist, since those patterns point to another kind of hair loss.
Sources
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information, §6.1 (Tables 3, 4 and 5; Hair Loss). DailyMed, version 19, effective June 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, §6.1 (Table 1; Hair Loss). DailyMed, version 40, effective August 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, prescribing information, §6.1 (Table 1; Hair Loss). DailyMed, version 10, effective July 2026. dailymed.nlm.nih.gov
- Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information, §6.2 Postmarketing Experience. DailyMed, version 20, effective June 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information, §6.2 Postmarketing Experience. DailyMed, version 40, effective August 2026. dailymed.nlm.nih.gov
- Novo Nordisk. SAXENDA (liraglutide) injection, prescribing information, §6.2 Postmarketing Experience. DailyMed, version 22, effective February 2026. dailymed.nlm.nih.gov
- Novo Nordisk. RYBELSUS and OZEMPIC (oral semaglutide) tablets, prescribing information, §6.2 Postmarketing Experience. DailyMed, version 14, effective January 2026. dailymed.nlm.nih.gov
- Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol. 2019;12:583-590. PubMed 31686886
- Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Ann Dermatol. 2024;36(6):384-388. PubMed 39623615
- Piraccini BM, Vañó-Galván S, Blume-Peytavi U, et al. Hair loss in patients on glucagon-like peptide 1 receptor agonists: understanding risks and managing outcomes. Dermatol Ther (Heidelb). 2026;16(7):3345-3360. Funded by Pierre Fabre Dermo-Cosmetics. PubMed 42249225
- Gupta AK, Teasell EM, Economopoulos V, et al. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2):368504261444578. PubMed 41998799
- Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. PubMed 42486607
- Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333. PubMed 42155605
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127
- Cohen-Kurzrock RA, Cohen PR. Bariatric surgery-induced telogen effluvium (Bar SITE): case report and a review of hair loss following weight loss surgery. Cureus. 2021;13(4):e14617. PubMed 34055500
- Katragadda R, Hayden J, Saltagi AK, et al. Nonscarring alopecia in adults treated with GLP-1s: a propensity score matched TriNetX cohort study. Laryngoscope. 2026 (online Aug 26). doi:10.1002/lary.70810. PubMed 42647098
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.